Uptravi

Uptravi

selexipag

Manufacturer:

Janssen-Cilag

Distributor:

DKSH
Concise Prescribing Info
Contents
Selexipag
Indications/Uses
Idiopathic & heritable pulmonary arterial HTN; pulmonary arterial HTN associated w/ connective tissue & congenital heart (w/ repaired shunts) disease; w/ drugs & toxins in patients w/ WHO functional class II, III or IV symptoms.
Dosage/Direction for Use
Individualized dose titration. Initially 200 mcg bid, approx 12 hr apart. Increased in increments of 200 mcg bid at wkly intervals. Max dose: 1,600 mcg bid. Moderate hepatic impairment (Child-Pugh Class B) Starting dose: 200 mcg once daily & increased at wkly intervals by increments of 200 mcg once daily.
Administration
Should be taken with food: Swallow whole, do not split/crush/chew.
Contraindications
Hypersensitivity. Severe CHD or unstable angina. MI w/in the last 6 mth. Decompensated cardiac failure. Severe arrhythmias. Cerebrovascular events (eg, transient ischaemic attack, stroke) w/in the last 3 mth. Congenital or acquired valvular defects w/ clinically relevant myocardial function disorders not related to pulmonary HTN. Concomitant use of strong inhibitors of CYP2C8 (eg, gemfibrozil).
Special Precautions
Patients on antihypertensive therapy or w/ resting hypotension, hypovolaemia, severe left ventricular outflow obstruction or autonomic dysfunction. Perform thyroid function tests if signs or symptoms of hyperthyroidism occurs. Discontinue if pulmonary veno-occlusive disease occurs. Concomitant use w/ moderate CYP2C8 (eg, clopidogrel, deferasirox, teriflunomide) inhibitors. May affect ability to drive & use machinery. Severe hepatic & renal impairment. Women of childbearing potential should use contraception during treatment. Pregnancy & lactation. Elderly >75 yr.
Adverse Reactions
Headache; flushing; nasopharyngitis (of non-infectious origin); diarrhoea, vomiting, nausea; jaw pain, myalgia, arthralgia, pain in extremity. Anaemia, decreased Hb; hyperthyroidism, decreased thyroid-stimulating hormone; decreased appetite, decreased wt; hypotension; nasal congestion; abdominal pain; rash, urticaria, erythema; pain.
Drug Interactions
Increased exposure w/ strong CYP2C8 inhibitor (eg, gemfibrozil); endothelin receptor antagonists & PDE-5 inhibitors. Decreased exposure w/ CYP2C8 inducers (eg, rifampicin, carbamazepine, phenytoin). Strong inhibitors of UGT1A3 & UGT2B7 (valproic acid, probenecid, & fluconazole).
MIMS Class
Other Cardiovascular Drugs
ATC Classification
B01AC27 - selexipag ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Presentation/Packing
Form
Uptravi FC tab 1,000 mcg
Packing/Price
6 × 10's
Form
Uptravi FC tab 1,200 mcg
Packing/Price
6 × 10's
Form
Uptravi FC tab 1,400 mcg
Packing/Price
6 × 10's
Form
Uptravi FC tab 1,600 mcg
Packing/Price
6 × 10's
Form
Uptravi FC tab 200 mcg
Packing/Price
14 × 10's;6 × 10's
Form
Uptravi FC tab 400 mcg
Packing/Price
6 × 10's
Form
Uptravi FC tab 600 mcg
Packing/Price
6 × 10's
Form
Uptravi FC tab 800 mcg
Packing/Price
6 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in